Dr. Mathias Hukkelhoven is an experienced global regulatory and drug development leader. He previously served as Senior Vice President, Global Regulatory, Safety & Biometrics at BMS and was also responsible for the R&D Group in BMS China and the Clinical Pharmacology and Pharmacometrics group. Math was accountable for setting regulatory strategy and driving execution of global regulatory and pharmacovigilance plans for BMS. He led the regulatory and development efforts across product development and commercialization processes to ensure optimal regulatory strategy and interactions at each step of the process.
Prior to joining BMS, Math was the chair of the Portfolio Stewardship Board at Novartis Pharma and served as the senior vice president and global head of drug regulatory affairs at Novartis from 2001 to 2009. He also worked at Hoffmann-La Roche (Switzerland) and Organon (Netherlands). Over the course of his career, Math contributed to more than 50 NCEs and hundreds of new indications and line extensions. He has participated in activities that have shaped health authority interactions, including serving as chair of the Regulatory Affairs Coordinating Committee at PhRMA, and recently as a PhRMA negotiator for the PDUFA VII negotiations with the FDA.
Math received his BS and PhD honors degrees in biology and biochemistry from Radboud University Nijmegen, the Netherlands.
Math also serves on the board of directors of Compugen Ltd, and since his retirement from BMS in July 2021, is a senior advisor to McKinsey and a R&D strategy advisor to LianBio.
